In this study we investigated the anti-Helicobacter pylori activity of four isopentenyloxycinnamyl derivatives from the Australian shrub Boronia pinnata Sm. (Rutaceae), structurally related to boropinic acid: (E)-3-(4-(3-methylbut-2-enyloxy)-3,5-dimethoxyphenyl)acrylaldehyde (1), boropinol C (2), boropinal (3) and boropinol A (4). In vitro growth of H. pylori strains 26695 and B128 was analyzed in liquid culture with increasing doses of these compounds. Bacterial morphology was visualized by scanning electron microscopy. The in vivo effects of the two most efficient molecules that reduced bacterial growth in vitro, compounds 3 and 4, were investigated on H. pylori gastric colonization in the mouse model. The presence of these compounds in the bacterial cultures led to alterations of bacterial surface and flagella. In vivo, both compounds 3 and 4 at 250 µM reduced significantly the ability of H. pylori to colonize the gastric mucosa of mice, compared with untreated ones. These data indicate that these natural isopentenyloxycinnamyl derivatives related to boropinic acid can be considered as novel antibacterial agents with anti-H. pylori activity.
Most of the aromatic compounds synthesized by plants are represented by phenols. These substances are the so-called "secondary metabolites" and in many cases serve for plant defence [1] . In recent decades, natural products containing a prenyloxy chain have been recognized as powerful molecules with biological and pharmacological activities [2a] . Many of these natural oxyprenylated products exhibit a wide range of anti-cancer [2b,2c], anti-inflammatory [2d, 2e], anti-microbial, and anti-fungal effects [2a] . Among them, 3-(4'-isopentenyloxy-3'-methoxyphenyl)-2-trans propenoic acid, commonly known as boropinic acid, is an active principle isolated from Boronia pinnata Sm. (Rutaceae) [2f, 2g] . Boropinic acid exhibits important biological activities [2a, 2c, 2d, 2e] , including anti-Helicobacter pylori activity [3a] , which we confirmed in the mouse model [3b] . The basic structural requirements for the observed activity of this class of molecules is an isopentenyloxy side chain, an ,β-unsaturated carboxylic acid, and an (E) geometry for the conjugated double bond [3a] . H. pylori infects half of the human population world-wide leading to chronic gastritis, ulcer disease, gastric cancer, and mucosa-associated lymphoid tissue (MALT) lymphoma [4] . Early eradication of the infection is of public health concern, in particular to prevent the development of gastric precancerous lesions. Indeed, in humans, several studies have highlighted the regression of precancerous lesions after the eradication of H. pylori infection [5a, 5b] . The classical treatment to eradicate the infection combines two antibiotics, namely amoxicillin with either clarithromycin or metronidazole, and a proton pump inhibitor (e.g. omeprazole) resulting in about 80% cure [6a] . However, the high incidence of antibiotic resistant strains illustrates the failure of this classical chemotherapeutic protocol [6b]. In line with this, alternative therapies based on the antimicrobial activity of phytochemicals deserve to be explored. Other compounds previously isolated from the roots of Boronia pinnata and belonging to the same chemical family as boropinic acid with an isopentenyloxy side chain, such as the sinapyl and coniferyl alcohol derivatives, boropinol A and C, and the aldehyde derivatives boropinal and (E)-3-(4-(3-methylbut-2-enyloxy)-3,5dimethoxyphenyl)acrylaldehyde can easily be obtained by chemical synthesis [2a] . In the present study, the effects of (E)-3-(4-(3-methylbut-2-enyloxy)-3,5dimethoxyphenyl)acrylaldehyde (1), boropinol C (2), boropinal (3), and boropinol A (4) ( Figure 1) were determined on H. pylori growth in vitro. In addition, using the wellvalidated mouse model of infection [7] , the effects of these natural substances on H. pylori gastric colonization were recorded, showing their anti-bacterial properties also in vivo.
As reported in Figure 2 , increasing doses of compounds 1 and 2 to a liquid culture of H. pylori strain 26695 progressively inhibited the bacterial growth, with drastic effects at the highest concentrations of 150 µM (P=0.016 and P=0.024) and 250 µM (P=0.011 and P=0.012), respectively. Compounds 3 and 4 were more efficient than compounds 1 and 2 in reducing H. pylori growth, since at the lowest concentration of 50 µM they drastically inhibited the bacterial growth (P=0.015 and P=0.01, respectively). The effects of compounds 3 and 4 were also investigated on the H. pylori strain B128, which in contrast to 26695, is able to chronically colonize the mouse gastric mucosa [8] . As shown in Figure 2 , the in vitro growth of strain B128 is reduced in the presence of compounds 3 and 4 at 100 µM (P=0.024 and P=0.037, respectively) and 250 µM (P=0.014 and P=0.029, respectively) as compared with untreated cultures. Strain B128 appeared less sensitive to the inhibitory effects of these molecules than strain 26695, since its growth was completely inhibited only by compound 3 at 250 µM. When bacteria were cultured for 12 hours before exposure with these compounds, their growth was not affected (data not shown). Under these conditions, the number of viable bacteria was 4.10 8 cfu/mL and 1.6 10 9 cfu/mL in control cultures for B128 and 26695 respectively, compared with 8 10 7 cfu/mL and 1.7 10 9 cfu/mL in compounds 3 and 4 treated cultures, respectively, either at 100 µM or 250 µM.
In order to characterize further the bacterial damaging effects of these compounds, we used scanning electron microscopy to visualize the morphological changes of strain B128 incubated with compound 3 or 4 (100µM for 24 h). Compared with untreated bacteria (Figures 3A to 3C), exposure to compound 3 led to severe morphological changes, including the formation of holes, as observed at the surface of treated bacteria ( Figures 3E and 3F , arrows). This should result in weakening bacterial surface structures leading to broken bacteria ( Figure 3E ). In addition, flagella were either absent or consistently shorter. Bacteria exposed to compound 4 exhibited less visible alterations (Figures 3G to 3I). However, under this condition, around 10% of bacteria were shorter in length and presented membrane blebbing ( Figure 3H ). Compared with untreated cultures ( Figure 3A ), bacteria presented either no or shorter flagella ( Figures 3G and 3H ). In addition, compound 4 led to veil-like structures at the bacterial surface ( Figure 3I ).
In vivo, various parameters, such as the bio-distribution of the compounds, their chemical stability and, in our case, their resistance to the extreme acidic conditions of the gastric lumen can influence their bioactivity. Consequently, the anti-H. pylori properties of a compound observed in vitro may not reflect strictly its in vivo activity. Using the mouse model, we investigated the consequences of exposure to compounds 3 and 4 on H. pylori gastric colonization at the two highest doses, 100 µM and 250 µM, previously tested in vitro ( Figure 2 ). The quantification of viable bacteria in the gastric mucosa of the infected-mice treated either with compound 3 or 4 (100 µM) did not show significant inhibition (Figure 4 ). H. pylori gastric colonization decreased significantly by 20-and 33-fold in infected-mice treated with 250 µM of compound 3 (mean = 0.025 10 6 cfu/g of tissue; P = 0.009) and compound 4 (mean = 0.015 10 6 cfu/g of tissue; P = 0.008), respectively, compared with non-treated infected-mice (mean = 0.50 10 6 cfu/g of tissue) ( Figure 4 ). In the compound 4 treated-group at 250 µM, gastric colonization was completely inhibited in 2/6 mice. No bacteria were detected in the gastric mucosa of naïve control mice (data not shown). In addition, all mice were alive and no toxic or side effects due to exposure to these molecules were observed by histopathological examination.
Prenyloxyphenylpropanoid derivatives represent a family of plant secondary metabolites with anti-cancer, anti-inflammatory, antimicrobial and anti-fungal properties [2]. Most of their biological activity is associated with their isopentenyloxy side chain [2].
In the present study, analysis of the anti-H. pylori effects of four prenyloxyphenylpropanoids plant derivatives, structurally related to Compared with untreated bacteria, cultures exposed to compound 3 showed alterations in the bacterial surface with the presence of holes at their surface (E and F, arrows), broken bacteria (E, short arrow), and either absence or presence of very short flagella.
In the presence of compound 4, the surface of bacteria seems altered (H, I) with veil structures and shorter bacteria with membrane blebbing, as indicated by arrow-heads (H). Flagella were also lacking or shorter in bacteria treated with compound 4.
Anti-Helicobacter pylori activity of isopentenyloxycinnamyl derivatives boropinic acid, showed that compounds 3 (boropinal) and 4 (boropinol A) were the most efficient in reducing H. pylori growth in vitro. Most importantly, they also reduced in vivo stomach colonization by H. pylori strain B128 in mice, at the highest dose tested of 250 µM. This dose is similar to the active quantity that inhibits the growth of H. pylori in vitro. Under the same conditions of liquid culture, the growth of H. pylori strain SS1 was also inhibited in the presence of boropinic acid at 200 µM (unpublished data). However, our previous in vivo study with H. pylori SS1 infected-mice showed that gastric colonization is inhibited at 5 µM of boropinic acid [3b]. Differences in the sensitivity of H. pylori strains to boropinic acid, boropinal and boropinol A may result from the specific chemical properties and reactivity of these molecules in vivo. Due to the pleiotropic biological activities of these compounds [2a] , during chronic H. pylori infection in vivo their anti-bacterial properties may be modulated not only by pharmacological factors related to their bio-distribution and metabolism, but also by their consequences on the cellular metabolism of the bacteria. Among the biological activities demonstrated for isopentenyloxycinnamyl derivatives, an inhibition of lipoxygenase activity [2e] and a modulating effect on human cytochrome P450 isozyme activity and expression has been reported [2h]. Boropinic acid, compound 3 and compound 4 have also been described as topical anti-inflammatory agents [2d]. Differences in the sensitivity of H. pylori strains to antimicrobial agents can also be explained by the high genetic diversity of this bacterium, which allows it to adapt to its host and to variation in its environment [9] . Boropinic acid, and compounds 3 and 4 revealed significant anti-H. pylori properties, leading to their classification as potent antiinfectious agents against this gastric pathogen. The characterization of this new class of antimicrobial compounds is specially important in terms of human health, due to the high incidence of H. pylori antibiotic resistant strains [6a,6b] . Furthermore, as cited previously, early eradication of H. pylori infection can also be beneficial in the context of gastric cancer prevention [5c].
Various anti-H. pylori agents have been shown to cause morphological changes to bacteria, as bacterial surface modifications [10] and conversion from the normal helical bacillary form to the unculturable coccoid form [11] . As observed by SEM, in vitro exposure to either compound 3 or compound 4 led to morphological alterations of the bacterial surface with more significant damage induced by compound 3. Flagella structures were either disrupted or absent. These alterations might completely inhibit the mobility of the bacteria, essential for their migration in the gastric niche and colonization of the host gastric mucosa [12a] . Exposure to compound 3 also induced the formation of hollows at the bacterial surface, as previously reported for H. pylori strains of different origins following exposure to 2-amino-phenoxazine [10] . The lipophilic properties of these isopentenyloxycinnamyl derivatives led us to postulate that they could interact with the bacterial membrane components, thus impairing bacterial mobility and survival. This could explain the inhibition of the ability of bacteria to colonize the gastric mucosa in exposed-mice. Damage to the bacterial outer membrane can also alter the bacterial flagella sheath, an extension of the bacterial outer membrane thought to protect the acid-labile flagellar structure from stomach acidity [12b]. Further investigations are needed to sharply elucidate the anti-bacterial action of these compounds. Under the conditions of our in vivo analysis, a complete inhibition of H. pylori gastric colonization by compounds 3 and 4 was not observed. However, their in vivo antibacterial activity led us to postulate that these molecules should improve the efficiency of classical antibiotherapy leading to a more efficient inhibition of the recurrence of the infection, thus contributing to limit further the increase of H. pylori antibiotic resistant strains.
In conclusion, our data led us to propose boropinal and boropinol A as efficient anti-microbial agents to improve the eradication rate and recurrence of H. pylori infection. Based on these findings, further developments of new structural analogues to optimize the antibacterial properties of these natural isopentenyloxycinnamyl derivatives will lead to alternative treatment for the eradication of H. pylori infection.
Experimental
Chemicals: Compounds 1 to 4 (Figure 1 ) were synthesized as previously described [2a,2c] . All analytical data recorded were in full agreement with those already reported for the same compounds [2c]. The purity of each molecule was recorded by gas chromatography-mass spectrometry (GC-MS) analysis and shown to be >98.5%. Concentrated stock solutions (100 mM) in dimethylsulfoxide were diluted in water and used in all experiments.
Bacterial strains and growth conditions:
The H. pylori strains 26695 (ATCC 700392) and B128 [8] were used in this study. Bacteria were grown on blood agar base 2 (Oxoid, Lyon, France) plates supplemented with 10% defibrinated horse blood (bioMérieux, Marcy l'Etoile, France) and an antibiotic-antifungal mixture consisting of vancomycin (10 mg/mL), polymyxin B (2.5IU/L), trimethoprim (5 mg/mL), and amphotericin B (4 mg/mL). The plates were incubated at 37°C for 24 to 48 h under microaerobic conditions (7% O 2 , 10% CO 2 ; Anoxomat TM system).
To determine growth kinetics, liquid bacterial cultures were inoculated with fresh plate-grown H. pylori strains at an initial optical density at 600 nm (OD600) of 0.1 into liquid brain heart infusion (BHI) (Oxoid) supplemented with 10% fetal calf serum (FCS). Increasing concentrations of compound 1 to compound 4 (50 µM to 250 µM) were added either at the beginning of the culture or on growing bacteria after 12 h of culture.
Electron microscopic analysis:
In order to examine the effects of compounds 3 and 4 on bacterial morphology, H. pylori strain B128 was grown in liquid culture for 24 h in the presence of 100 µM of either compound 3 or 4, as described above. 1 h in 1% osmium tetroxide in cacodylate buffer and rinsed with distilled water. Samples were dehydrated through a series of ethanol solutions from 25% to 95% in successive steps of 5 min incubation, and 10 min in 100% ethanol. The samples were then dried using CO 2 and coated twice with carbon using a Baltec Med 010 evaporator. They were analyzed with a JEOL 6700F field emission scanning electron microscope at 5 Kv.
Infection of mice and treatment:
This study was carried out in strict accordance with the recommendations in the Specific Guide Pasteur, approved by the Regional Ethical Committee for Animal Experimentation (Comité Régional d'Ethique pour l'Expérimentation Animale (CREEA) Ile de France) according to European directive (2010/63/UE) and the corresponding French law on scientific experiments using animals (decrees in 1988) and their protection. Five-week-old specific pathogen-free C57BL/6 male mice were purchased from Charles River Laboratories (France). The animals were housed in polycarbonate cages and acclimatized for one week before starting the experiments. Five groups of 6 mice were orogastrically inoculated with 100 µL of a suspension of B128 (10 8 cfu/mL), previously grown on blood agar plates. Seven days later, 2 groups were treated orogastrically daily with 150 µL of compound 3 and 4 at 100 µM (168 µg/kg body-weight/day and 169 µg/kg body-weight/day, respectively) and 250 µM (420 µg/kg body-weight/day and 422.5 µg/kg body-weight/day, respectively) for 2 consecutive weeks. The untreated groups, one non-infected and one H. pylori-infected, received 150 µL vehicle during the 2 weeks of oral treatment. To allow long-term treatment and to avoid over-stressing the animals, the 2 treated-groups received drinking water supplemented with either compound 3 or 4 at either 100 µM or 250 µM for the 2 following weeks until sacrifice. The stomach of each mouse was isolated and fragments including antrum and fundus parts were crushed. The quantification of H. pylori gastric colonization was performed as described previously [7] .
Statistical analysis:
The Mann-Whitney test and two-tailed t-test were used for statistical analysis. A P-value ≤ 0.05 was considered significant.
